{"id":342661,"date":"2025-08-20T18:45:53","date_gmt":"2025-08-20T18:45:53","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-biontech-se\/"},"modified":"2025-08-20T18:45:53","modified_gmt":"2025-08-20T18:45:53","slug":"how-to-buy-biontech-se","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/","title":{"rendered":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334027,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-342661","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"BioNTech SE (BNTX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i mRNA teknolojisi liderine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"BioNTech SE (BNTX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu yenilik\u00e7i mRNA teknolojisi liderine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"A\u015f\u0131 teknolojisinde devrim yaratan \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? BioNTech SE (BNTX) sadece COVID-19 ba\u015far\u0131s\u0131ndan daha fazlas\u0131n\u0131 temsil ediyor - kanser tedavisinde iddial\u0131 hedefleri olan \u00f6nc\u00fc bir mRNA t\u0131bb\u0131 g\u00fcc\u00fc. Bu Alman biyoteknoloji devi, pandemi kahraman\u0131ndan onkoloji yenilik\u00e7isine d\u00f6n\u00fc\u015f\u00fcyor ve yat\u0131r\u0131mc\u0131lara en son t\u0131bbi teknolojiye eri\u015fim sunuyor. BioNTech'in neden dikkatinizi hak etti\u011fini ve bu yat\u0131r\u0131m f\u0131rsat\u0131na stratejik olarak nas\u0131l yakla\u015faca\u011f\u0131m\u0131z\u0131 ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"A\u015f\u0131 teknolojisinde devrim yaratan \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? BioNTech SE (BNTX) sadece COVID-19 ba\u015far\u0131s\u0131ndan daha fazlas\u0131n\u0131 temsil ediyor - kanser tedavisinde iddial\u0131 hedefleri olan \u00f6nc\u00fc bir mRNA t\u0131bb\u0131 g\u00fcc\u00fc. Bu Alman biyoteknoloji devi, pandemi kahraman\u0131ndan onkoloji yenilik\u00e7isine d\u00f6n\u00fc\u015f\u00fcyor ve yat\u0131r\u0131mc\u0131lara en son t\u0131bbi teknolojiye eri\u015fim sunuyor. BioNTech'in neden dikkatinizi hak etti\u011fini ve bu yat\u0131r\u0131m f\u0131rsat\u0131na stratejik olarak nas\u0131l yakla\u015faca\u011f\u0131m\u0131z\u0131 ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 BioNTech Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>20 A\u011fustos 2025 itibar\u0131yla BioNTech SE (BNTX), NASDAQ borsas\u0131nda <strong>111,40 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck f\u0131rsat\u0131n\u0131z. BioNTech o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar \u00f6nemli fiyat hareketleri yarat\u0131yor.<\/p> <p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><br\/> 4 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131 ilgin\u00e7 bir desen g\u00f6sterdi - EPS tahminlerini ka\u00e7\u0131rmas\u0131na ra\u011fmen (-1,60 $ vs. beklenen -1,41 $), hisse senedi ertesi g\u00fcn %0,9 artarak 111,05 $ oldu (<a href=\"https:\/\/www.benzinga.com\/analyst-stock-ratings\/price-target\/25\/08\/46866575\/these-analysts-revise-their-forecasts-on-biontech-after-q2-results\">Benzinga Analizi<\/a>). Neden? \u00c7\u00fcnk\u00fc gelir beklentileri 306,46 milyon $ ile 161,26 milyon $ tahminini ezdi, bu da yat\u0131r\u0131mc\u0131lar\u0131n biyoteknolojide k\u0131sa vadeli kay\u0131plardan ziyade b\u00fcy\u00fcme potansiyelini de\u011ferli g\u00f6rd\u00fc\u011f\u00fcn\u00fc kan\u0131tlad\u0131.<\/p> <p>Bu desen yeni de\u011fil. Son alt\u0131 kazan\u00e7 d\u00f6ng\u00fcs\u00fcnde BioNTech \u015funlar\u0131 g\u00f6sterdi:<\/p> <ul> <li><strong>%50 pozitif tepki<\/strong> kazan\u00e7 sonras\u0131 ilk 3 g\u00fcn i\u00e7inde<\/li> <li><strong>%57 pozitif momentum<\/strong> 10-30 g\u00fcnl\u00fck d\u00f6nemlerde<\/li> <li>Tek g\u00fcnl\u00fck maksimum kazan\u00e7lar <strong>%5,39<\/strong> seviyesine ula\u015ft\u0131<\/li> <\/ul> <p>Ders? Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar \u00e7eyreklik kay\u0131plar\u0131n \u00f6tesinde boru hatt\u0131 potansiyeline ve stratejik ortakl\u0131klara bakar.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: \u015eubat-A\u011fustos 2025<\/h2> <p>BioNTech hisseleri son bir y\u0131lda etkileyici bir <strong>%25,83 kazan\u00e7<\/strong> sa\u011flad\u0131, \u00f6zellikle son aylarda g\u00fc\u00e7l\u00fc performans g\u00f6sterdi:<\/p> <p><strong>\u015eubat 2025:<\/strong> ~89 $ (k\u0131\u015f konsolidasyonu sonras\u0131)<br\/> <strong>Nisan 2025:<\/strong> ~97 $ (erken boru hatt\u0131 iyimserli\u011fi)<br\/> <strong>Haziran 2025:<\/strong> ~105 $ (BMS ortakl\u0131k duyurusu heyecan\u0131)<br\/> <strong>A\u011fustos 2025:<\/strong> 111,40 $ (kazan\u00e7 sonras\u0131 g\u00fc\u00e7lenme)<\/p> <p>Bu y\u00fckseli\u015f e\u011filimi, BioNTech'in COVID'e ba\u011f\u0131ml\u0131 olmaktan \u00e7e\u015fitlendirilmi\u015f onkoloji oyuncusuna ge\u00e7i\u015fine artan g\u00fcveni yans\u0131t\u0131yor. Hisse senedi, 52 haftal\u0131k en d\u00fc\u015f\u00fck 81,20 $ ve en y\u00fcksek 131,49 $ aras\u0131nda sa\u011fl\u0131kl\u0131 bir i\u015flem aral\u0131\u011f\u0131n\u0131 koruyor ve \u015fu anda b\u00fcy\u00fcme i\u00e7in alan b\u0131rakarak ortada konumlan\u0131yor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve boru hatt\u0131 geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p> <p><strong>2025 Y\u0131l Sonu:<\/strong> 139-150 $ (y\u00fczde 25-35 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br\/> Analistler ortalama hedef fiyat\u0131 139,49 $ olan \"G\u00fc\u00e7l\u00fc Al\" derecesini koruyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/bntx\/forecast\/\">StockAnalysis Konsens\u00fcs\u00fc<\/a>). Son Bristol Myers Squibb ortakl\u0131\u011f\u0131 an\u0131nda do\u011frulama ve nakit giri\u015fi sa\u011fl\u0131yor.<\/p> <p><strong>2026 Tahmini:<\/strong> 160-180 $<br\/> BNT327 Faz 3 denemelerinde ilerledik\u00e7e ve muhtemel ilk onaylar\u0131 ald\u0131k\u00e7a, \u00f6nemli bir yeniden de\u011ferleme bekleniyor. BMS'den al\u0131nan 1,5 milyar $ \u00f6n \u00f6deme, seyrelme olmadan geli\u015ftirmeyi finanse ediyor.<\/p> <p><strong>2028 Projeksiyonu:<\/strong> 200-250 $<br\/> \u00c7e\u015fitlendirilmi\u015f onkoloji boru hatt\u0131ndan birden fazla \u00fcr\u00fcn lansman\u0131 bekleniyor. BioNTech, mRNA a\u015f\u0131lar\u0131n\u0131n \u00f6tesinde \u00e7ok \u00fcr\u00fcnl\u00fc bir \u015firkete d\u00f6n\u00fc\u015f\u00fcyor.<\/p> <p><strong>2030 Vizyonu:<\/strong> 300 $+<br\/> Birden fazla kanser t\u00fcr\u00fcnde onkoloji boru hatt\u0131 potansiyelinin tam ger\u00e7ekle\u015fmesi. Ki\u015fiselle\u015ftirilmi\u015f mRNA kanser a\u015f\u0131lar\u0131 standart bak\u0131m haline geliyor.<\/p> <p><strong>Sonu\u00e7:<\/strong> Bu uzun vadeli bir b\u00fcy\u00fcme hikayesi. D\u00fc\u015f\u00fc\u015flerde biriktirin ve 3-5 y\u0131ll\u0131k d\u00f6n\u00fc\u015f\u00fcm i\u00e7in tutun.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131:<\/strong> \u0130la\u00e7 adaylar\u0131n\u0131n %90'\u0131 ba\u015far\u0131s\u0131z olur - BNT327 gerilemeleri hisseyi \u00e7\u00f6kertebilir<\/li> <li><strong>Reg\u00fclasyon Engelleri:<\/strong> FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yenilik\u00e7i mekanizmalar i\u00e7in<\/li> <li><strong>COVID Gelir D\u00fc\u015f\u00fc\u015f\u00fc:<\/strong> Pandemi k\u00e2rlar\u0131ndan uzakla\u015fma finansal bask\u0131 yarat\u0131yor<\/li> <li><strong>Rekabet:<\/strong> Moderna, Pfizer ve onlarca startup benzer mRNA f\u0131rsatlar\u0131n\u0131n pe\u015finde<\/li> <li><strong>Y\u00fcksek Harcama Oran\u0131:<\/strong> Son \u00e7eyrekte 509,1 milyon \u20ac Ar-Ge giderleri devam eden finansman gerektiriyor<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>BMS Ortakl\u0131\u011f\u0131 Do\u011frulamas\u0131:<\/strong> 1,5 milyar $ \u00f6n \u00f6deme + 7,6 milyar $ potansiyel kilometre ta\u015flar\u0131 = b\u00fcy\u00fck g\u00fcven oyu<\/li> <li><strong>\u00c7e\u015fitlendirilmi\u015f Boru Hatt\u0131:<\/strong> 10'dan fazla endikasyonda 20+ klinik deneme tek varl\u0131k riskini azalt\u0131yor<\/li> <li><strong>Mali G\u00fc\u00e7:<\/strong> 16,0 milyar \u20ac nakit rezervleri \u00e7ok y\u0131ll\u0131 finansman sa\u011fl\u0131yor<\/li> <li><strong>Yetim \u0130la\u00e7 Tan\u0131m\u0131:<\/strong> FDA taraf\u0131ndan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri i\u00e7in BNT327 tan\u0131nmas\u0131<\/li> <li><strong>ASCO 2025 Verileri:<\/strong> Tedavisi zor mezotelyoma i\u00e7in umut verici sonu\u00e7lar<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyotek hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> M\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine haftal\u0131k 100-200 $ al\u0131m yap\u0131n<\/li> <li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> Daha iyi risk-getiri oran\u0131 i\u00e7in 105 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde al\u0131m yap\u0131n<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn:<\/strong> Bu 3-5 y\u0131ll\u0131k bir hikaye, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li> <\/ol> <p>Esprili deneyimli tavsiye: \"BioNTech ticareti, parafini kururken para\u015f\u00fctle atlamak gibidir - uzun s\u0131k\u0131c\u0131 d\u00f6nemler, ard\u0131ndan ani korku anlar\u0131. Anahtar, korkutucu anlarda panik yapmamakt\u0131r.\"<\/p>  <h2>\u2705 BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellspacing=\"0\" cellpadding=\"5\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir ticaret platformu se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td> <td>Do\u011fru belgelerle genellikle 1-2 g\u00fcn s\u00fcrer<\/td> <\/tr> <tr> <td>3<\/td> <td>Fon yat\u0131r\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>\"BNTX\" aramas\u0131 yap\u0131n<\/td> <td>Sadece \"BioNTech\" de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Limit emirleri kullan\u0131n<\/td> <td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td> <\/tr> <tr> <td>6<\/td> <td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td> <td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td> <\/tr> <tr> <td>7<\/td> <td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td> <td>Do\u011fru hisse say\u0131s\u0131n\u0131 ald\u0131\u011f\u0131n\u0131zdan emin olun<\/td> <\/tr> <tr> <td>8<\/td> <td>Fiyat uyar\u0131lar\u0131 kurun<\/td> <td>D\u00fc\u015f\u00fc\u015flerde pozisyonunuzu art\u0131rmak i\u00e7in takip edin<\/td> <\/tr> <tr> <td>9<\/td> <td>Tezinizi belgeleyin<\/td> <td>Gelecek referans i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td> <\/tr> <tr> <td>10<\/td> <td>Sab\u0131rl\u0131 olun<\/td> <td>Biyotek yat\u0131r\u0131m aylar\/y\u0131llar ister, g\u00fcnler de\u011fil<\/td> <\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, BioNTech gibi \u015firketlerde pozisyon olu\u015fturmak i\u00e7in birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum depozito miktar\u0131 5 $<\/strong> - Daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce stratejileri minimal riskle test edin<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Basit belge y\u00fcklemesi ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong> - BNTX gibi pahal\u0131 hisselerin tam pay\u0131na ihtiya\u00e7 duymadan k\u0131s\u0131mlar\u0131n\u0131 sat\u0131n al\u0131n<\/li> <li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> - Kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k ile karlar\u0131n\u0131za eri\u015fin<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k biyotek yat\u0131r\u0131m\u0131n\u0131 yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131larken, BioNTech'in d\u00f6n\u00fc\u015f\u00fcm hikayesinden yararlanmak isteyen deneyimli yat\u0131r\u0131mc\u0131lara geli\u015fmi\u015f ara\u00e7lar sunar.<\/p>  <h2>\ud83c\udf0d 2025'te BioNTech: Pandeminin \u00d6tesinde<\/h2> <p>BioNTech, \"COVID a\u015f\u0131 \u015firketi\" olmaktan kapsaml\u0131 bir imm\u00fcnoterapi liderine ba\u015far\u0131l\u0131 bir \u015fekilde d\u00f6n\u00fc\u015ft\u00fc. \u015eirket art\u0131k mRNA terap\u00f6tikleri, protein bazl\u0131 ila\u00e7lar, h\u00fccre tedavileri ve k\u00fc\u00e7\u00fck molek\u00fcller olmak \u00fczere d\u00f6rt farkl\u0131 teknoloji platformu i\u015fletiyor.<\/p> <p>Mevcut odak alanlar\u0131 \u015funlard\u0131r:<\/p> <ul> <li><strong>BNT327<\/strong>: PD-L1 ve VEGF-A hedefleyen \u00e7oklu kat\u0131 t\u00fcm\u00f6rler i\u00e7in yeni nesil bispesifik antikor<\/li> <li><strong>Bireyselle\u015ftirilmi\u015f kanser a\u015f\u0131lar\u0131<\/strong>: E\u015fsiz t\u00fcm\u00f6r profillerini hedefleyen ki\u015fiselle\u015ftirilmi\u015f mRNA tedavileri<\/li> <li><strong>Enfeksiyon hastal\u0131klar\u0131 boru hatt\u0131<\/strong>: S\u0131tma, t\u00fcberk\u00fcloz ve di\u011fer k\u00fcresel sa\u011fl\u0131k \u00f6ncelikleri i\u00e7in devam eden geli\u015ftirme<\/li> <li><strong>\u00dcretim geni\u015flemesi<\/strong>: K\u00fcresel a\u015f\u0131 eri\u015fimini art\u0131rmak i\u00e7in Afrika'da mRNA \u00fcretim giri\u015fimleri<\/li> <\/ul> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> BioNTech'in Mainz merkezinde, katlar aras\u0131nda kendini UV-C \u0131\u015f\u0131k teknolojisiyle otomatik dezenfekte eden laboratuvar asans\u00f6rleri bulunuyor - pandemi d\u00f6neminde geli\u015ftirilen ve enfeksiyon hastal\u0131klar\u0131 ara\u015ft\u0131rma tesisleri i\u00e7in kal\u0131c\u0131 altyap\u0131 haline gelen bir yenilik.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 BioNTech Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>20 A\u011fustos 2025 itibar\u0131yla BioNTech SE (BNTX), NASDAQ borsas\u0131nda <strong>111,40 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>3 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck f\u0131rsat\u0131n\u0131z. BioNTech o tarihte 3. \u00e7eyrek kazan\u00e7lar\u0131n\u0131 a\u00e7\u0131klayacak ve tarihsel olarak bu raporlar \u00f6nemli fiyat hareketleri yarat\u0131yor.<\/p>\n<p><strong>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/strong><br \/> 4 A\u011fustos 2025 tarihli 2. \u00e7eyrek kazan\u00e7lar\u0131 ilgin\u00e7 bir desen g\u00f6sterdi &#8211; EPS tahminlerini ka\u00e7\u0131rmas\u0131na ra\u011fmen (-1,60 $ vs. beklenen -1,41 $), hisse senedi ertesi g\u00fcn %0,9 artarak 111,05 $ oldu (<a href=\"https:\/\/www.benzinga.com\/analyst-stock-ratings\/price-target\/25\/08\/46866575\/these-analysts-revise-their-forecasts-on-biontech-after-q2-results\">Benzinga Analizi<\/a>). Neden? \u00c7\u00fcnk\u00fc gelir beklentileri 306,46 milyon $ ile 161,26 milyon $ tahminini ezdi, bu da yat\u0131r\u0131mc\u0131lar\u0131n biyoteknolojide k\u0131sa vadeli kay\u0131plardan ziyade b\u00fcy\u00fcme potansiyelini de\u011ferli g\u00f6rd\u00fc\u011f\u00fcn\u00fc kan\u0131tlad\u0131.<\/p>\n<p>Bu desen yeni de\u011fil. Son alt\u0131 kazan\u00e7 d\u00f6ng\u00fcs\u00fcnde BioNTech \u015funlar\u0131 g\u00f6sterdi:<\/p>\n<ul>\n<li><strong>%50 pozitif tepki<\/strong> kazan\u00e7 sonras\u0131 ilk 3 g\u00fcn i\u00e7inde<\/li>\n<li><strong>%57 pozitif momentum<\/strong> 10-30 g\u00fcnl\u00fck d\u00f6nemlerde<\/li>\n<li>Tek g\u00fcnl\u00fck maksimum kazan\u00e7lar <strong>%5,39<\/strong> seviyesine ula\u015ft\u0131<\/li>\n<\/ul>\n<p>Ders? Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar \u00e7eyreklik kay\u0131plar\u0131n \u00f6tesinde boru hatt\u0131 potansiyeline ve stratejik ortakl\u0131klara bakar.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: \u015eubat-A\u011fustos 2025<\/h2>\n<p>BioNTech hisseleri son bir y\u0131lda etkileyici bir <strong>%25,83 kazan\u00e7<\/strong> sa\u011flad\u0131, \u00f6zellikle son aylarda g\u00fc\u00e7l\u00fc performans g\u00f6sterdi:<\/p>\n<p><strong>\u015eubat 2025:<\/strong> ~89 $ (k\u0131\u015f konsolidasyonu sonras\u0131)<br \/> <strong>Nisan 2025:<\/strong> ~97 $ (erken boru hatt\u0131 iyimserli\u011fi)<br \/> <strong>Haziran 2025:<\/strong> ~105 $ (BMS ortakl\u0131k duyurusu heyecan\u0131)<br \/> <strong>A\u011fustos 2025:<\/strong> 111,40 $ (kazan\u00e7 sonras\u0131 g\u00fc\u00e7lenme)<\/p>\n<p>Bu y\u00fckseli\u015f e\u011filimi, BioNTech&#8217;in COVID&#8217;e ba\u011f\u0131ml\u0131 olmaktan \u00e7e\u015fitlendirilmi\u015f onkoloji oyuncusuna ge\u00e7i\u015fine artan g\u00fcveni yans\u0131t\u0131yor. Hisse senedi, 52 haftal\u0131k en d\u00fc\u015f\u00fck 81,20 $ ve en y\u00fcksek 131,49 $ aras\u0131nda sa\u011fl\u0131kl\u0131 bir i\u015flem aral\u0131\u011f\u0131n\u0131 koruyor ve \u015fu anda b\u00fcy\u00fcme i\u00e7in alan b\u0131rakarak ortada konumlan\u0131yor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve boru hatt\u0131 geli\u015fmelerine dayanarak, beklenenler \u015funlard\u0131r:<\/p>\n<p><strong>2025 Y\u0131l Sonu:<\/strong> 139-150 $ (y\u00fczde 25-35 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Analistler ortalama hedef fiyat\u0131 139,49 $ olan &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecesini koruyor (<a href=\"https:\/\/stockanalysis.com\/stocks\/bntx\/forecast\/\">StockAnalysis Konsens\u00fcs\u00fc<\/a>). Son Bristol Myers Squibb ortakl\u0131\u011f\u0131 an\u0131nda do\u011frulama ve nakit giri\u015fi sa\u011fl\u0131yor.<\/p>\n<p><strong>2026 Tahmini:<\/strong> 160-180 $<br \/> BNT327 Faz 3 denemelerinde ilerledik\u00e7e ve muhtemel ilk onaylar\u0131 ald\u0131k\u00e7a, \u00f6nemli bir yeniden de\u011ferleme bekleniyor. BMS&#8217;den al\u0131nan 1,5 milyar $ \u00f6n \u00f6deme, seyrelme olmadan geli\u015ftirmeyi finanse ediyor.<\/p>\n<p><strong>2028 Projeksiyonu:<\/strong> 200-250 $<br \/> \u00c7e\u015fitlendirilmi\u015f onkoloji boru hatt\u0131ndan birden fazla \u00fcr\u00fcn lansman\u0131 bekleniyor. BioNTech, mRNA a\u015f\u0131lar\u0131n\u0131n \u00f6tesinde \u00e7ok \u00fcr\u00fcnl\u00fc bir \u015firkete d\u00f6n\u00fc\u015f\u00fcyor.<\/p>\n<p><strong>2030 Vizyonu:<\/strong> 300 $+<br \/> Birden fazla kanser t\u00fcr\u00fcnde onkoloji boru hatt\u0131 potansiyelinin tam ger\u00e7ekle\u015fmesi. Ki\u015fiselle\u015ftirilmi\u015f mRNA kanser a\u015f\u0131lar\u0131 standart bak\u0131m haline geliyor.<\/p>\n<p><strong>Sonu\u00e7:<\/strong> Bu uzun vadeli bir b\u00fcy\u00fcme hikayesi. D\u00fc\u015f\u00fc\u015flerde biriktirin ve 3-5 y\u0131ll\u0131k d\u00f6n\u00fc\u015f\u00fcm i\u00e7in tutun.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131klar\u0131:<\/strong> \u0130la\u00e7 adaylar\u0131n\u0131n %90&#8217;\u0131 ba\u015far\u0131s\u0131z olur &#8211; BNT327 gerilemeleri hisseyi \u00e7\u00f6kertebilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri:<\/strong> FDA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yenilik\u00e7i mekanizmalar i\u00e7in<\/li>\n<li><strong>COVID Gelir D\u00fc\u015f\u00fc\u015f\u00fc:<\/strong> Pandemi k\u00e2rlar\u0131ndan uzakla\u015fma finansal bask\u0131 yarat\u0131yor<\/li>\n<li><strong>Rekabet:<\/strong> Moderna, Pfizer ve onlarca startup benzer mRNA f\u0131rsatlar\u0131n\u0131n pe\u015finde<\/li>\n<li><strong>Y\u00fcksek Harcama Oran\u0131:<\/strong> Son \u00e7eyrekte 509,1 milyon \u20ac Ar-Ge giderleri devam eden finansman gerektiriyor<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>BMS Ortakl\u0131\u011f\u0131 Do\u011frulamas\u0131:<\/strong> 1,5 milyar $ \u00f6n \u00f6deme + 7,6 milyar $ potansiyel kilometre ta\u015flar\u0131 = b\u00fcy\u00fck g\u00fcven oyu<\/li>\n<li><strong>\u00c7e\u015fitlendirilmi\u015f Boru Hatt\u0131:<\/strong> 10&#8217;dan fazla endikasyonda 20+ klinik deneme tek varl\u0131k riskini azalt\u0131yor<\/li>\n<li><strong>Mali G\u00fc\u00e7:<\/strong> 16,0 milyar \u20ac nakit rezervleri \u00e7ok y\u0131ll\u0131 finansman sa\u011fl\u0131yor<\/li>\n<li><strong>Yetim \u0130la\u00e7 Tan\u0131m\u0131:<\/strong> FDA taraf\u0131ndan k\u00fc\u00e7\u00fck h\u00fccreli akci\u011fer kanseri i\u00e7in BNT327 tan\u0131nmas\u0131<\/li>\n<li><strong>ASCO 2025 Verileri:<\/strong> Tedavisi zor mezotelyoma i\u00e7in umut verici sonu\u00e7lar<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek volatiliteye sahip biyotek hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> M\u00fckemmel giri\u015f zaman\u0131n\u0131 beklemek yerine haftal\u0131k 100-200 $ al\u0131m yap\u0131n<\/li>\n<li><strong>Fiyat Uyar\u0131lar\u0131 Kurun:<\/strong> Daha iyi risk-getiri oran\u0131 i\u00e7in 105 $ alt\u0131ndaki d\u00fc\u015f\u00fc\u015flerde al\u0131m yap\u0131n<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn:<\/strong> Bu 3-5 y\u0131ll\u0131k bir hikaye, h\u0131zl\u0131 bir i\u015flem de\u011fil<\/li>\n<\/ol>\n<p>Esprili deneyimli tavsiye: &#8220;BioNTech ticareti, parafini kururken para\u015f\u00fctle atlamak gibidir &#8211; uzun s\u0131k\u0131c\u0131 d\u00f6nemler, ard\u0131ndan ani korku anlar\u0131. Anahtar, korkutucu anlarda panik yapmamakt\u0131r.&#8221;<\/p>\n<h2>\u2705 BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"5\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Do\u011fru belgelerle genellikle 1-2 g\u00fcn s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;BNTX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece &#8220;BioNTech&#8221; de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Limit emirleri kullan\u0131n<\/td>\n<td>Fazla \u00f6deme yapmamak i\u00e7in maksimum al\u0131\u015f fiyat\u0131n\u0131z\u0131 belirleyin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Emir detaylar\u0131n\u0131 g\u00f6zden ge\u00e7irin<\/td>\n<td>Komisyon \u00fccretleri ve takas tarihlerini kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Al\u0131m\u0131 ger\u00e7ekle\u015ftirin<\/td>\n<td>Do\u011fru hisse say\u0131s\u0131n\u0131 ald\u0131\u011f\u0131n\u0131zdan emin olun<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun<\/td>\n<td>D\u00fc\u015f\u00fc\u015flerde pozisyonunuzu art\u0131rmak i\u00e7in takip edin<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Tezinizi belgeleyin<\/td>\n<td>Gelecek referans i\u00e7in neden ald\u0131\u011f\u0131n\u0131z\u0131 yaz\u0131n<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Sab\u0131rl\u0131 olun<\/td>\n<td>Biyotek yat\u0131r\u0131m aylar\/y\u0131llar ister, g\u00fcnler de\u011fil<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Uygun?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, BioNTech gibi \u015firketlerde pozisyon olu\u015fturmak i\u00e7in birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito miktar\u0131 5 $<\/strong> &#8211; Daha b\u00fcy\u00fck miktarlara ge\u00e7meden \u00f6nce stratejileri minimal riskle test edin<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Basit belge y\u00fcklemesi ile dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>Par\u00e7al\u0131 hisse imkan\u0131<\/strong> &#8211; BNTX gibi pahal\u0131 hisselerin tam pay\u0131na ihtiya\u00e7 duymadan k\u0131s\u0131mlar\u0131n\u0131 sat\u0131n al\u0131n<\/li>\n<li><strong>100+ para \u00e7ekme y\u00f6ntemi<\/strong> &#8211; Kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k ile karlar\u0131n\u0131za eri\u015fin<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k biyotek yat\u0131r\u0131m\u0131n\u0131 yeni ba\u015flayanlar i\u00e7in eri\u015filebilir k\u0131larken, BioNTech&#8217;in d\u00f6n\u00fc\u015f\u00fcm hikayesinden yararlanmak isteyen deneyimli yat\u0131r\u0131mc\u0131lara geli\u015fmi\u015f ara\u00e7lar sunar.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te BioNTech: Pandeminin \u00d6tesinde<\/h2>\n<p>BioNTech, &#8220;COVID a\u015f\u0131 \u015firketi&#8221; olmaktan kapsaml\u0131 bir imm\u00fcnoterapi liderine ba\u015far\u0131l\u0131 bir \u015fekilde d\u00f6n\u00fc\u015ft\u00fc. \u015eirket art\u0131k mRNA terap\u00f6tikleri, protein bazl\u0131 ila\u00e7lar, h\u00fccre tedavileri ve k\u00fc\u00e7\u00fck molek\u00fcller olmak \u00fczere d\u00f6rt farkl\u0131 teknoloji platformu i\u015fletiyor.<\/p>\n<p>Mevcut odak alanlar\u0131 \u015funlard\u0131r:<\/p>\n<ul>\n<li><strong>BNT327<\/strong>: PD-L1 ve VEGF-A hedefleyen \u00e7oklu kat\u0131 t\u00fcm\u00f6rler i\u00e7in yeni nesil bispesifik antikor<\/li>\n<li><strong>Bireyselle\u015ftirilmi\u015f kanser a\u015f\u0131lar\u0131<\/strong>: E\u015fsiz t\u00fcm\u00f6r profillerini hedefleyen ki\u015fiselle\u015ftirilmi\u015f mRNA tedavileri<\/li>\n<li><strong>Enfeksiyon hastal\u0131klar\u0131 boru hatt\u0131<\/strong>: S\u0131tma, t\u00fcberk\u00fcloz ve di\u011fer k\u00fcresel sa\u011fl\u0131k \u00f6ncelikleri i\u00e7in devam eden geli\u015ftirme<\/li>\n<li><strong>\u00dcretim geni\u015flemesi<\/strong>: K\u00fcresel a\u015f\u0131 eri\u015fimini art\u0131rmak i\u00e7in Afrika&#8217;da mRNA \u00fcretim giri\u015fimleri<\/li>\n<\/ul>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek:<\/strong> BioNTech&#8217;in Mainz merkezinde, katlar aras\u0131nda kendini UV-C \u0131\u015f\u0131k teknolojisiyle otomatik dezenfekte eden laboratuvar asans\u00f6rleri bulunuyor &#8211; pandemi d\u00f6neminde geli\u015ftirilen ve enfeksiyon hastal\u0131klar\u0131 ara\u015ft\u0131rma tesisleri i\u00e7in kal\u0131c\u0131 altyap\u0131 haline gelen bir yenilik.<\/p>\n"},"faq":[{"question":"BioNTech hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"BioNTech hisselerini sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi olan bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"BNTX\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 kurarak pozisyonunuzu y\u00f6netin."},{"question":"BioNTech'in 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 139-150 $ aral\u0131\u011f\u0131nda olup %25-35 y\u00fckseli\u015f potansiyeli ta\u015f\u0131maktad\u0131r. 2026'da 160-180 $, 2028'de 200-250 $ ve 2030'da 300 $ \u00fczeri hedeflenmektedir."},{"question":"BioNTech yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon engelleri, COVID gelirlerindeki d\u00fc\u015f\u00fc\u015f, rekabet ve y\u00fcksek Ar-Ge harcamalar\u0131 yer almaktad\u0131r."},{"question":"Yeni ba\u015flayanlar BioNTech hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, fiyat uyar\u0131lar\u0131 kurmak ve uzun vadeli d\u00fc\u015f\u00fcnmek yeni ba\u015flayanlar i\u00e7in \u00f6nerilen stratejilerdir."},{"question":"Pocket Option BioNTech yat\u0131r\u0131m\u0131 i\u00e7in neden uygundur?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunarak yeni yat\u0131r\u0131mc\u0131lar\u0131n BioNTech gibi \u015firketlerde pozisyon olu\u015fturmas\u0131n\u0131 kolayla\u015ft\u0131r\u0131r."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"BioNTech hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"BioNTech hisselerini sat\u0131n almak i\u00e7in NASDAQ eri\u015fimi olan bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, fon yat\u0131r\u0131n, \"BNTX\" sembol\u00fc ile arama yap\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve fiyat uyar\u0131lar\u0131 kurarak pozisyonunuzu y\u00f6netin."},{"question":"BioNTech'in 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda hisse fiyat\u0131 139-150 $ aral\u0131\u011f\u0131nda olup %25-35 y\u00fckseli\u015f potansiyeli ta\u015f\u0131maktad\u0131r. 2026'da 160-180 $, 2028'de 200-250 $ ve 2030'da 300 $ \u00fczeri hedeflenmektedir."},{"question":"BioNTech yat\u0131r\u0131m\u0131nda hangi riskler vard\u0131r?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon engelleri, COVID gelirlerindeki d\u00fc\u015f\u00fc\u015f, rekabet ve y\u00fcksek Ar-Ge harcamalar\u0131 yer almaktad\u0131r."},{"question":"Yeni ba\u015flayanlar BioNTech hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"Portf\u00f6y\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyet ortalamas\u0131 yapmak, fiyat uyar\u0131lar\u0131 kurmak ve uzun vadeli d\u00fc\u015f\u00fcnmek yeni ba\u015flayanlar i\u00e7in \u00f6nerilen stratejilerdir."},{"question":"Pocket Option BioNTech yat\u0131r\u0131m\u0131 i\u00e7in neden uygundur?","answer":"Pocket Option d\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, par\u00e7al\u0131 hisse al\u0131m\u0131 ve \u00e7ok say\u0131da para \u00e7ekme y\u00f6ntemi sunarak yeni yat\u0131r\u0131mc\u0131lar\u0131n BioNTech gibi \u015firketlerde pozisyon olu\u015fturmas\u0131n\u0131 kolayla\u015ft\u0131r\u0131r."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T18:45:53+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-20T18:45:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\",\"name\":\"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"datePublished\":\"2025-08-20T18:45:53+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp\",\"width\":1408,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/","og_locale":"tr_TR","og_type":"article","og_title":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-20T18:45:53+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-20T18:45:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/","name":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r - BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","datePublished":"2025-08-20T18:45:53+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals5.webp","width":1408,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-biontech-se\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"BioNTech SE (BNTX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; BioNTech SE (BNTX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":342658,"slug":"how-to-buy-biontech-se","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu BioNTech SE (BNTX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu BioNTech SE (BNTX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-biontech-se\/"},"pt_AA":{"locale":"pt_AA","id":342655,"slug":"how-to-buy-biontech-se","post_title":"Como comprar a\u00e7\u00f5es da BioNTech SE (BNTX) - Investimento em a\u00e7\u00f5es da BioNTech SE (BNTX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-biontech-se\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=342661"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/342661\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334027"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=342661"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=342661"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=342661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}